BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announces that it has completed its acquisition of Astria Therapeutics, Inc., initially announced on October 14, 2025. The transaction strengthens its position as a leader in hereditary angioedema (HAE) and enhances the company’s long-term growth trajectory. BioCryst adds navenibart, a late-stage, long-acting plasma kallikrein inhibitor currently in Phase 3 clinical development, to its HAE portfolio. The potential to be the first HAE therapy with every-three and every-six month dosing, combined with a high level of attack control, positions navenibart to significantly improve the treatment experience for HAE patients.
Read the full article: BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema //
Source: https://www.globenewswire.com/news-release/2026/01/23/3224805/29446/en/BioCryst-Completes-Acquisition-of-Astria-Therapeutics-Expanding-Leadership-in-Hereditary-Angioedema.html